Journal article
In COVID-19, tocilizumab reduces all-cause mortality at 28 d.
Abstract
SOURCE CITATION: Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021;3:CD013881. 33734435.
Authors
Fernando SM; Rochwerg B
Journal
Annals of Internal Medicine, Vol. 174, No. 6,
Publisher
American College of Physicians
Publication Date
6 2021
DOI
10.7326/acpj202106150-063
ISSN
1056-8751